TW202317184A - 用於治療異位性皮膚炎和相關障礙之方法 - Google Patents

用於治療異位性皮膚炎和相關障礙之方法 Download PDF

Info

Publication number
TW202317184A
TW202317184A TW111121662A TW111121662A TW202317184A TW 202317184 A TW202317184 A TW 202317184A TW 111121662 A TW111121662 A TW 111121662A TW 111121662 A TW111121662 A TW 111121662A TW 202317184 A TW202317184 A TW 202317184A
Authority
TW
Taiwan
Prior art keywords
binding protein
subject
weeks
antibody
dose
Prior art date
Application number
TW111121662A
Other languages
English (en)
Chinese (zh)
Inventor
湯瑪斯 馬克
莉絲 索德柏
克里斯汀 傑瑞高 歐蘭德
Original Assignee
英商梅迪繆思有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 英商梅迪繆思有限公司 filed Critical 英商梅迪繆思有限公司
Publication of TW202317184A publication Critical patent/TW202317184A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
TW111121662A 2021-06-11 2022-06-10 用於治療異位性皮膚炎和相關障礙之方法 TW202317184A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2108379.5A GB202108379D0 (en) 2021-06-11 2021-06-11 Methods for treating a topic dermatitis and related disorders
GB2108379.5 2021-06-11

Publications (1)

Publication Number Publication Date
TW202317184A true TW202317184A (zh) 2023-05-01

Family

ID=76954592

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111121662A TW202317184A (zh) 2021-06-11 2022-06-10 用於治療異位性皮膚炎和相關障礙之方法

Country Status (9)

Country Link
US (1) US20250059269A1 (cg-RX-API-DMAC7.html)
EP (1) EP4351641A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024522620A (cg-RX-API-DMAC7.html)
AU (1) AU2022289697A1 (cg-RX-API-DMAC7.html)
CA (1) CA3221119A1 (cg-RX-API-DMAC7.html)
GB (1) GB202108379D0 (cg-RX-API-DMAC7.html)
IL (1) IL309053A (cg-RX-API-DMAC7.html)
TW (1) TW202317184A (cg-RX-API-DMAC7.html)
WO (1) WO2022258814A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260234236A1 (en) * 2023-02-13 2026-08-13 Intervet Inc. Canine antibodies to canine il-13

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
KR101363777B1 (ko) 2005-09-30 2014-02-14 메디뮨 리미티드 인터루킨―13 항체 조성물
WO2017139290A1 (en) * 2016-02-10 2017-08-17 Medimmune, Llc Tralokinumab delivery device
JP2020509025A (ja) 2017-03-01 2020-03-26 メドイミューン・リミテッドMedImmune Limited モノクローナル抗体製剤

Also Published As

Publication number Publication date
EP4351641A1 (en) 2024-04-17
GB202108379D0 (en) 2021-07-28
JP2024522620A (ja) 2024-06-21
AU2022289697A1 (en) 2023-12-21
US20250059269A1 (en) 2025-02-20
WO2022258814A1 (en) 2022-12-15
CA3221119A1 (en) 2022-12-15
IL309053A (en) 2024-02-01

Similar Documents

Publication Publication Date Title
US11167004B2 (en) Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
US20190367622A1 (en) Methods for Treating Skin Infection by Administering an IL-4R Antagonist
US20230115617A1 (en) Anti-il-36r antibodies for treatment of palmoplantar pustulosis
RU2759630C2 (ru) Способы лечения тяжелого атопического дерматита путем введения ингибитора il-4r
US20230102151A1 (en) Methods for treating atopic dermatitis by administering an il-4r antagonist
US20230167171A1 (en) Methods for treating atopic dermatitis by administering an il-4r antagonist
US12083161B2 (en) Treating IgE-mediated allergic diseases
US12187788B2 (en) Methods for treating atopic dermatitis and related disorders
US20250059269A1 (en) Methods for treating atopic dermatitis and related disorders
EP4126943B1 (en) Methods for treating atopic dermatitis and related disorders
US20240400669A1 (en) Methods for treating atopic dermatitis and related disorders
RU2801204C2 (ru) Способ лечения атопического дерматита посредством введения ингибитора ил-4r
RU2845158C1 (ru) Способы лечения атопического дерматита путем введения антагониста il-4r